uniQure price target raised to $70 from $25 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on uniQure (QURE) to $70 from $25 and keeps a Buy rating on the shares. The firm also named uniQure a top pick or 2025 ahead of the next regulatory update for the AMT-130. AMT-130 appears well-positioned to become first disease-modifying treatment in Huntington’s disease, the analyst tells investors in a research note. H.C. Wainwright believes an accelerated pathway to potential approval of AMT-130 has emerged.